🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Pfizer on track for U.S. vaccine boosters, Moderna lagging, Fauci says

Published 09/05/2021, 12:16 PM
Updated 09/05/2021, 01:50 PM
© Reuters. FILE PHOTO: Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks during a Senate Health, Education, Labor, and Pensions Committee hearing at the Dirksen Senate Office Building in Washington, D.C., U.S., July 20,
PFE
-
MRNA
-

By Raphael Satter

WASHINGTON (Reuters) - Top U.S. infectious disease expert Dr. Anthony Fauci said on Sunday that officials were likely to soon get the regulatory go-ahead to administer COVID-19 vaccine booster shots made by Pfizer (NYSE:PFE), although Moderna (NASDAQ:MRNA) booster could take a little longer.

Asked on CBS' "Face the Nation," about President Joe Biden's goal to give booster shots starting Sept. 20, Fauci said that "in some respects" that remained the plan.

But he said that while Pfizer-BioNTech has submitted the necessary data on booster shots to the Food and Drug Administration (FDA), Moderna has yet to complete the process. Fauci said he hopes to give both vaccines when boosters doses roll out, but if Moderna does not complete the process before Sept. 20, then Moderna boosters will be given later.

Moderna and the FDA did not immediately return emails seeking comment. In a statement released Wednesday, Moderna said it had "initiated its submission" of booster data to the FDA.

How - or even whether - to administer boosters https://www.reuters.com/world/us/fda-vaccine-advisers-face-thorny-question-are-covid-19-boosters-needed-2021-09-03 has emerged as a thorny issue as COVID-19 continues to kill unvaccinated people around the world https://tmsnrt.rs/34pvUyi.

Last month the Biden administration announced it would start offering boosters to Americans by Sept. 20, usurping the process https://www.reuters.com/world/us/fda-vaccine-advisers-face-thorny-question-are-covid-19-boosters-needed-2021-09-03 by which the FDA and the U.S. Centers for Disease Control and Prevention usually decide on such issues, current and former FDA scientists and CDC advisory panel members have told Reuters.

Scientists are still debating how much additional immunity boosters provide and whether all Americans should get another shot, rather than just those at high risk of severe illness.

© Reuters. FILE PHOTO: Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks during a Senate Health, Education, Labor, and Pensions Committee hearing at the Dirksen Senate Office Building in Washington, D.C., U.S., July 20, 2021. Stefani Reynolds/Pool via REUTERS

Speaking Sunday, Fauci emphasized that both boosters were assumed to be safe, but that the FDA and other officials would study the data to make sure.

"When you're dealing with allowing the American public to receive an intervention, you want to make sure you're absolutely certain," he said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.